Vasculitis: Clinical Trials

11 trials for Vasculitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 unknown. 11 Phase 3, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 311Unknown 11
Phase 23Unknown 3

Follow Vasculitis: new trials by email Literature Review of Vasculitis trials Research Report on Vasculitis

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Comparison of Tofacitinib and Prednisolone in the Treatment of Active Takayasu's Arteritis
Tofacitinib 5 MG, Prednisolone, Placebo of tofacitinib 5mg - Takayasu Arteritis
Phase 3UnknownChinese SLE Treatment And Research Group502023-01-202023-03-01
COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases
COVID-19 vaccine - Rheumatoid Arthritis, Autoimmune Rheumatologic Disease
Phase 2 / Phase 3UnknownPaul R Fortin2872022-03-092023-01-17
Drug-eluting Balloon for Treatment of Non-atherosclerotic Renal Artery Stenosis
Angioplasty with paclitaxel eluting balloon, Angioplasty with plain old balloon - Hypertension, Renovascular
Phase 3UnknownPeking Union Medical College Hospital902019-10-012020-04-29
Exploring Durable Remission With Rituximab in Antineutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis
Rituximab, endoxan, Methylprednisolone - ANCA Associated Vasculitis
Phase 3UnknownLeiden University Medical Center1002019-05-032023-12-14
The Effect of Some Drugs Used in Treatment of Vasculitis on the Complement System in Children
Ibuprofen, Prednisone, Methotrexate - Vasculitis
Phase 3UnknownAssiut University702018-11-112021-02-15
Anti-inflammatory Treatment for Inactive Takayasu Arteritis
Prednisone, cyclophosphamide - Takayasu Arteritis, Anti-Inflammatory Agents
Phase 2 / Phase 3UnknownChinese Academy of Medical Sciences, Fuwai Hospital402018-06-012018-06-08
The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach
5 mg prednisone, 0 mg prednisone - Granulomatosis With Polyangiitis, Wegener Granulomatosis
Phase 3UnknownUniversity of South Florida122014-02-172024-07-29
A Trial to Evaluate the Efficacy of Immunoglobulin Plus Steroid for Prevention of Coronary Artery Abnormalities in Taiwanese Refractory Kawasaki Disease (RAST Study)
Prednisolone, immunoglobulin - Kawasaki Disease, Steroid
Phase 3UnknownNational Taiwan University Hospital1002013-10-172017-06-27
Safety and Efficacy of Oral Versus Intravenous Amiodarone in the Treatment of AF
Amiodarone - Atrial Fibrillation
Phase 3UnknownWestern Galilee Hospital-Nahariya1042013-05-012013-03-25
Peripheral Venous Catheter Trial: 3 Day Versus No Routine Change
Extending peripheral intravenous (IV) cannula dwell times - Phlebitis
Phase 2 / Phase 3UnknownRoyal Brisbane and Women's Hospital2002004-03-012005-06-24
WEGENT - Comparison of Methotrexate or Azathioprine as Maintenance Therapy for ANCA-Associated Vasculitides
Azathioprine: 2 mg/kg/day, methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week - Systemic Wegener's Granulomatosis
Phase 3UnknownHospices Civils de Lyon1261999-01-012007-10-10

Narrower conditions

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (3)  ·  Takayasu Arteritis (3)  ·  Granulomatosis with Polyangiitis (2)  ·  Phlebitis (2)  ·  Systemic Vasculitis (2)  ·  Arthritis, Rheumatoid (1)  ·  Atrial Fibrillation (1)  ·  Cardiovascular Diseases (1)  ·  Fibromuscular Dysplasia (1)  ·  Hypertension, Renovascular (1)  ·  Lung Diseases (1)  ·  Lung Diseases, Interstitial (1)  ·  Lupus Erythematosus, Systemic (1)  ·  MASS syndrome (1)

Broader conditions

Cardiovascular Diseases (10)  ·  Vascular Diseases (10)  ·  Skin Diseases (8)  ·  Skin and Connective Tissue Diseases (8)  ·  Skin Diseases, Vascular (7)  ·  Autoimmune Diseases (4)  ·  Immune System Diseases (4)  ·  Aortic Arch Syndromes (3)  ·  Aortic Diseases (3)  ·  Arteritis (3)  ·  Female Urogenital Diseases (2)  ·  Female Urogenital Diseases and Pregnancy Complications (2)  ·  Kidney Diseases (2)  ·  Male Urogenital Diseases (2)

Interventions

Prednisolone (3)  ·  Prednisone (3)  ·  Cyclophosphamide (2)  ·  Methotrexate (2)  ·  Adrenal Cortex Hormones (1)  ·  Amiodarone (1)  ·  Angioplasty (1)  ·  Azathioprine (1)  ·  COVID-19 Vaccines (1)  ·  Glucocorticoids (1)  ·  Ibuprofen (1)  ·  Immunoglobulins (1)  ·  Methylprednisolone (1)  ·  Methylprednisolone Hemisuccinate (1)  ·  Rituximab (1)

Sponsors

Assiut University (1)  ·  Chinese Academy of Medical Sciences, Fuwai Hospital (1)  ·  Chinese SLE Treatment And Research Group (1)  ·  Hospices Civils de Lyon (1)  ·  Leiden University Medical Center (1)  ·  National Taiwan University Hospital (1)  ·  Paul R Fortin (1)  ·  Peking Union Medical College Hospital (1)  ·  Royal Brisbane and Women's Hospital (1)  ·  University of South Florida (1)  ·  Western Galilee Hospital-Nahariya (1)

Countries

China (2)  ·  Australia (1)  ·  Canada (1)  ·  Egypt (1)  ·  France (1)  ·  Israel (1)  ·  Netherlands (1)  ·  Taiwan (1)  ·  United States (1)

Top investigators

Atar Shaul, MD (1)  ·  Jeffrey P Krischer, PhD (1)  ·  Lilach Shema-didi, PhD (1)  ·  Mei-Hwan Wu, MD, PhD (1)  ·  Ming-Tai Lin, MD, PhD (1)  ·  Nicola Makhoul, MD (1)  ·  Paul R Fortin, MD,MPH,FRCPC (1)  ·  Peter A Merkel, MD, MPH (1)  ·  Safiea AF El-Deeb, PROF (1)  ·  Xinping Tian, MD (1)  ·  Xiongjing Jiang, MD (1)  ·  Yuehong Zheng, MD (1)

Results publications

PMID 19109574, PMID 28246067, PMID 36130755, PMID 39425055

NIH funding

R01HL115041 (1)